

OPEXA THERAPEUTICS, INC.

FORM 8-K (Current report filing)

Filed 11/29/05 for the Period Ending 11/23/05

Address	2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS, TX 77381
Telephone	(281) 272-9331
CIK	0001069308
Symbol	OPXA
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

PHARMAFRONTIERS CORP.

FORM 8-K (Unscheduled Material Events)

Filed 11/29/2005 For Period Ending 11/23/2005

Address	2635 CRESCENT RIDGE DRIVE THE WOODLANDS, Texas 77381
Telephone	(281)272-9331
CIK	0001069308
Fiscal Year	12/31

Powered By **EDGAR**
Online

<http://www.edgar-online.com/>

© Copyright 2005. All Rights Reserved.

Distribution and use of this document restricted under EDGAR Online's Terms of Use.

UNITED STATES
SECURITIES EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 23, 2005.

PHARMAFRONTIERS CORP

(Exact name of registrant as specified in its charter)

Texas	000-25513	76-0333165
-----	-----	-----
(State of organization)	(Commission File Number)	(IRS Employer Identification No.)
2635 N. Crescent Ridge Drive The Woodlands, Texas		77381
-----		-----
(Address of principal executive offices)		(Zip Code)

Registrant's Telephone Number, including area code: (281) 272-9331

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

The Special Committee of the Board of Directors with its independent counsel completed its review of statements made by two former directors of the Company in connection with their resignations in October, 2005. Promptly after receipt of the statements, the Board had appointed the Special Committee to review the statements and provide a report to the Board. The Special Committee immediately retained as independent counsel, the firm of Baker & McKenzie, to assist with the review. The Special Committee completed its review and has delivered its report and conclusions to the Board. Based on the information reviewed, the Special Committee and its counsel have not found evidence relative to the statements that would provide the basis for a claim of a breach of fiduciary duty, violations of applicable law, or violation of the company's code of ethics governing the Code of executive conduct.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMAFRONTIERS CORP

By: /s/ David B. McWilliams

David B. McWilliams, Chief Executive Officer

DATE: November 29, 2005

End of Filing

Powered By  EDGAR Online

© 2005 | EDGAR Online, Inc.